Encompass Health: A Proven Bed-Building Compounder Priced With No Margin of Safety

Revenue per discharge is more difficult to decompose. The 10-Q says the increase “primarily” reflected higher reimbursement rates and patient mix, but management does not disclose a precise acuity-versus-rate bridge. A bounded estimate is still possible. Medicare fee-for-service was 65.8% of Q2 revenue, and the FY2026 IRF PPS final rule raised the base payment update 2.6%, consisting of a 3.3% market-basket update less a 0.7 percentage-point productivity adjustment. Applied mechanically to the Medicare revenue share, that rate update alone represents about 1.7 percentage points of blended revenue growth, before case-mix and geographic effects. Medicare Advantage and managed care supplied another 26.9% of revenue, and Encompass Health has said typical managed-care rate increases have recently been in the 2%–4% range. A reasonable inference is that contractual/administrative rate movement explains roughly 2.2–2.8 percentage points of the 3.9% revenue-per-discharge increase, leaving roughly 1.1–1.7 points for acuity, payer/geographic mix and other case-mix effects. That split is an analytical estimate, not a management disclosure.

Demand does not appear to be the near-term constraint. Capacity increasingly is. At June 30, Encompass Health operated 176 hospitals, 109 wholly owned and 67 jointly owned, with ownership interests in the consolidated joint ventures ranging from 50.0% to 97.5%. It had 18 additional IRFs or related facilities under development as of early August. Through the first half it opened three hospitals totaling 139 beds and added 54 beds at existing facilities; management expects five more hospitals and more than 100 additional existing-hospital beds before the end of 2026.

The headline 77.4% occupancy rate can make the network look less capacity-constrained than it is. Encompass Health evaluates expansion before a hospital reaches full occupancy because construction takes time; management said it has lowered the practical evaluation threshold from roughly 80%–85% occupancy to 70%–75%. New hospitals have on average reached positive four-wall EBITDA by around month six and more than 70% occupancy by around month ten. Management also said around 60 hospitals were operating above 90% occupancy. The business therefore has spare capacity in the aggregate but material local bottlenecks. Sustaining mid- to high-single-digit discharge growth increasingly requires new beds in the right referral markets rather than simply filling an idle national bed base.

Construction economics are becoming a larger part of the equity story. Encompass Health’s 2023 Investor Day gave average de novo cost per bed, including land, construction, equipment and pre-opening expenses, of $725,000 for 2020–2021 projects, $850,000 for 2022–2023 and $1.2 million for projects scheduled for 2024–2025. That latest formal benchmark implies about $60 million for a typical 50-bed facility before any subsequent cost inflation. The same presentation showed a staffing model of roughly 100 FTEs for a 50-bed de novo. Project-level cash flows are not disclosed granularly enough for me to calculate realized ROIC on the most recent 2025–2026 openings, so the disclosed month-six EBITDA and month-ten occupancy ramp are therefore more reliable project-performance markers than an invented ROIC number.

The capital burden is substantial but mostly growth-related. Encompass Health spent about $736 million on property, equipment and intangible assets in 2025 and now expects $920 million–$995 million in 2026. Only $225 million–$240 million is classified as nondiscretionary or maintenance expenditure. At midpoints, maintenance is about 24% of the 2026 capital budget and roughly $725 million is development, capacity, technology or other discretionary/growth capital. Projects already under construction at June 30 required roughly another $422 million over the following two years.

Labor sits on the other side of the model. This remains a nurse- and therapist-intensive operation, but the extraordinary post-pandemic agency-labor problem is fading. Contract-labor FTEs fell from 425 in 2023 to 355 in 2025 and to 333 in Q2 2026; the Q2 figure was 12.1% below the prior year and only about 1.1% of total FTEs. Q2 premium-labor expense was approximately $25 million, down $2.6 million year over year, and management described Q2 as the eleventh consecutive quarter of year-over-year premium-labor decline. Employees per occupied bed were 3.34 versus 3.39 a year earlier.

This is partly cyclical normalization and partly operational work. Recruitment conditions have improved markedly relative to the pandemic period; Encompass Health has also invested in recruiting analytics, local-market marketing, retention and staffing productivity. I would not underwrite perpetual labor deflation. Contract-labor rates have stabilized and ordinary employee wages can continue rising even while expensive temporary labor falls. The more durable gain is that Encompass Health is once again filling more shifts with internal employees. That lowers volatility and improves staffing continuity, but it does not remove wage inflation from the cost structure.

Reimbursement is the dominant external variable. Medicare fee-for-service accounted for 65.8% of Q2 2026 revenue, Medicare Advantage 16.2%, managed care 10.7% and Medicaid 3.1%. That puts Medicare-related revenue at 82% of the total before counting other government-linked arrangements. CMS finalized a 2.6% FY2026 IRF PPS update and, on July 30, 2026, finalized a 2.3% FY2027 update, based on a 3.2% market basket less a 0.9-point productivity adjustment. CMS estimates the latter will raise aggregate IRF payments by about $340 million; it becomes relevant to Encompass Health beginning October 1, 2026. CMS is also soliciting information on broader IRF case-mix/payment reform, which is exploratory rather than settled policy.

The “60% rule” remains in force. To qualify for IRF PPS classification, at least 60% of an IRF’s inpatient population must require rehabilitation for one or more of 13 specified conditions. CMS’s FY2027 materials continue to provide the compliance coding framework effective October 1, 2026; I found no 2026 final or proposed rule replacing the 60% threshold. Current policy discussion around IRF case-mix reform should therefore not be described as an announced repeal of the 60% rule.

Medicare Advantage is the more awkward structural issue. Encompass Health reported that approximately 54% of Medicare beneficiaries were enrolled in Medicare Advantage during 2025, yet MA generated only 16.4% of Encompass Health’s 2025 revenue and 16.2% in Q2 2026. Management says MA plans generally reimburse below traditional Medicare, although the rate differential has narrowed, and that preauthorization results in a lower referral-to-admission conversion rate. The company also warns that vertically integrated MA insurers owning home-health assets may have an incentive to steer patients toward a lower-cost home setting.

There is evidence that some denials are contestable. In a nine-market “admit and appeal” pilot, 298 patients had been admitted through July 2026; 144 appeals had been adjudicated and Encompass Health had won 128, an 89% success rate among adjudicated cases. That is encouraging evidence about clinical eligibility, but it also illustrates the economic friction: an appeal consumes administrative time and creates uncertainty that straightforward Medicare fee-for-service admission does not. Encompass Health does not publicly disclose a clean Medicare-Advantage-specific length of stay, so I do not infer one from the aggregate 11.9-day Q2 figure.

Financially, the pure-play IRF business has been better than the old conglomerate framing suggested. From 2020 through 2025, recast/post-spin inpatient revenue compounded about 10.5% annually and adjusted EBITDA roughly 12.7%. Cash generation strengthened alongside earnings. The most recent three years are especially clean: revenue increased from $4.80 billion in 2023 to $5.94 billion in 2025, adjusted EBITDA from $971 million to $1.268 billion, and continuing-operations diluted EPS attributable to Encompass Health from $3.59 to $5.55.

Q2 2026 kept the growth going, with the EBITDA spread closed rather than widened. Revenue grew 9.6%, adjusted EBITDA 9.2% to $348 million and adjusted EPS 10.7% to $1.55. Cash from operations rose 4.6% to $282.6 million while adjusted free cash flow declined 4.8% to $177 million. Management raised full-year revenue guidance to $6.410–$6.490 billion, adjusted EBITDA to $1.365–$1.395 billion and adjusted EPS to $6.02–$6.25.

Capital allocation is moving from balance-sheet repair toward simultaneous growth investment and shareholder return. The company repurchased approximately $74.2 million of shares during Q2 and $145.8 million during the first half. On July 23 the board expanded aggregate repurchase authorization to $1 billion and raised the quarterly dividend from $0.19 to $0.21 a share. The authorization has no fixed expiry, and the board can suspend or terminate it. Net leverage was about 1.9 times after a 2026 refinancing that included $500 million of 5.875% notes due 2034 and redemption of $400 million of 4.5% notes due 2028.

The market has recognized the improvement. Secondary market-price data show EHC gaining roughly 12.6% on August 6 after Q2 results, closing around $124.8; that differs slightly from the supplied $124.93/12.65% press-summary figure, so I treat “about 12.6%” as the defensible level rather than claiming false precision. At the August 24 close of $120.92, the stock trades at approximately 19.7 times the midpoint of 2026 adjusted EPS guidance, with an annualized dividend yield of only about 0.7%.

The bull/bear debate has moved with it. The argument is no longer whether the company can recover from pandemic labor pressure or whether the Enhabit separation will work. The question now is how long roughly 9%–10% revenue growth can continue when the two big external variables, Medicare payment and nursing/therapy wages, sit outside management’s direct control. Bulls see a fragmented, capacity-constrained IRF market, favorable demographics, falling premium labor and a proven de novo machine. Bears see a business with administratively set prices, a rising Medicare Advantage gatekeeper, nearly $1 billion of annual capex and an equity multiple already assuming the operating machine keeps working.

Qualitative portrait: high-quality compounding growth, but with regulated pricing and construction intensity that prevent it from being a low-risk compounder. The “high-quality” part comes from durable discharge demand, improving labor productivity, high cash conversion, a repeatable construction/ramp process and a clean post-spin business model. The restraint comes from valuation and the fact that the company does not own its pricing power.

Vertical history and financial review

Encompass Health’s history splits into two radically different halves. The first is the HealthSouth story: entrepreneurial creation, acquisition-fueled expansion and one of the most consequential accounting scandals in U.S. healthcare. The second is the reconstruction: hospital rationalization, governance repair, a move back toward inpatient rehabilitation, a temporary attempt to build an integrated post-acute platform, and finally the 2022 decision to return to a pure IRF model.

The company traces its roots to Birmingham in 1984 and Richard Scrushy, whose background included hospital administration and rehabilitation services. The early idea was economically sensible: rehabilitation could increasingly be delivered outside a traditional acute hospital at a lower cost, while demographic and hospital-cost pressures were expanding demand. HealthSouth bought its first inpatient rehabilitation hospital in 1986.

HealthSouth began public trading on NASDAQ as HSRC on September 24, 1986 and moved to the New York Stock Exchange on August 11, 1989. The company’s present investor FAQ confirms those dates. The exact IPO offer price and amount raised are not reliably recoverable from the primary electronic SEC archive available for this research, so I do not reproduce secondary figures as though they were verified primary data. The current post-scandal common shares began trading on the NYSE on October 26, 2006.

The early model was expansionist. Rehabilitation demand was rising, and HealthSouth used acquisitions and new facilities to turn a regional concept into a national network. What this era proved was that rehabilitation could be standardized, branded and scaled. What it did not prove was the credibility of reported earnings.

The break arrived publicly in March 2003. The SEC alleged that shortly after HealthSouth became public, senior personnel began manipulating earnings to meet Wall Street expectations; for 1999 through the second quarter of 2002, the SEC alleged at least $1.4 billion of overstatement in income before taxes and minority interests. A Justice Department account of the investigation later noted guilty pleas by 15 former HealthSouth executives, including all five former CFOs involved in the period.

This episode genuinely changed the company’s fate. Trading collapsed, credibility disappeared and post-2003 management inherited a business whose first task was survival and financial reconstruction rather than growth. The history still matters because it explains why Encompass Health’s modern governance culture places unusual emphasis on compliance, centralized operating systems and auditability. As a predictor of current accounting behavior it matters much less: the people, controls, business mix, audit environment and capital structure have changed dramatically over more than two decades.

The reconstruction phase gradually stripped away businesses that did not belong in a focused rehabilitation company. Mark Tarr, who joined the organization in the 1990s and became president of the inpatient division in 2004, was part of that operational continuity. He became president and CEO in December 2016 after serving as COO. What matters is less the length of that tenure than the domain knowledge behind it: the present chief executive came up through hospital operations rather than arriving from an unrelated financial or acquisition background.

A second strategic turn began in 2014, when HealthSouth agreed to pay about $750 million for Encompass Home Health and Hospice, at the time a large Medicare-focused home-health operator with about 140 locations across 13 states. The transaction was intended to move HealthSouth across the post-acute continuum, allowing it to own both intensive inpatient rehabilitation and lower-acuity care delivered at home.

That strategy eventually reshaped the corporate identity. HealthSouth announced the Encompass Health name in 2017 and began trading as EHC in January 2018, creating a single brand across inpatient rehabilitation and home health/hospice. The logic was understandable: acute hospitals increasingly wanted coordinated post-acute discharge partners, and owning multiple settings promised referral and care-continuity benefits.

The integrated-platform thesis did not survive. On July 1, 2022, Encompass Health completed the separation of the home-health and hospice business as Enhabit, distributing one EHAB share for every two EHC shares. After the separation, EHC operated a single inpatient rehabilitation segment. Enhabit itself did not last long as a public peer: it agreed in February 2026 to a $13.80-per-share cash acquisition by Kinderhook Industries at an enterprise value of about $1.1 billion, and the transaction closed in May 2026. As of this research date EHAB is a historical comparator, not a live listed valuation peer.

The 2022 separation is not cosmetic history. It changed what investors own: EHC is now a regulated hospital-capacity compounder rather than a diversified post-acute portfolio.

The refocused company has since concentrated capital on de novo hospitals, bed additions and acute-care health-system joint ventures. The numerical pattern is unusually consistent.

† 2020–2022 figures use the company’s continuing-operations/inpatient presentation after Enhabit was classified as discontinued operations. Adjusted EBITDA is non-GAAP. Operating cash flow is consolidated and therefore includes cash generated by consolidated joint ventures before distributions to noncontrolling owners. Sources: Encompass Health 2022 and 2025 Forms 10-K.

From 2020 through 2025, inpatient revenue compounded at about 10.5% and adjusted EBITDA at about 12.7%. The spread indicates modest operating leverage rather than a spectacular margin transformation. The more important change is that growth remained double-digit or close to it after the pandemic distortion faded: inpatient revenue increased 10.4% in 2023, 11.4% in 2024 and 10.1% in 2025.

Recent growth is visibly tied to patient throughput. Discharges reached 229,480 in 2023, 248,498 in 2024 and 263,299 in 2025. Net patient revenue per discharge increased from $20,454 to $21,048 and then $21,862. Occupancy rose from 72.1% in 2023 to 74.6% in 2024 and 75.9% in 2025, even as licensed beds increased from 10,778 to 11,465. The company managed to add beds and fill them at the same time, which is better evidence of underlying demand than revenue growth alone.

Cash conversion also improved. Cash from operations rose from $851 million in 2023 to $1.003 billion in 2024 and $1.176 billion in 2025. The ratio of operating cash flow to continuing net income attributable to Encompass Health was approximately 1.88 times in 2021, 2.54 times in 2022, 2.34 times in 2023, 2.19 times in 2024 and 2.07 times in 2025; the five-year aggregate ratio is about 2.18 times.

That ratio overstates cash conversion to common shareholders somewhat because operating cash flow is consolidated while attributable net income deducts minority owners’ economic claims. In 2025, for example, consolidated net income was $759.1 million, $192.9 million went to noncontrolling interests and $566.2 million was attributable to Encompass Health. The same issue appears in Q2 2026: noncontrolling interests received $53.5 million of quarterly net income, while approximately $154.5 million was attributable to EHC common holders.

This makes EBITDA especially easy to misuse. EHC consolidates hospitals it controls, including many JVs, so consolidated revenue and EBITDA include 100% of those hospitals’ operating results while EPS deducts minority shareholders’ claims. At June 30, nonredeemable NCI on the balance sheet was approximately $805.5 million and redeemable NCI about $57.9 million. A valuation built on consolidated enterprise value/EBITDA should include the economic value of those minority interests; a simple market-cap-plus-net-debt numerator against 100% of EBITDA makes EHC look cheaper than it is.

The balance sheet is healthy enough to fund construction but not so underleveraged that financing ceases to matter. Management reported net leverage of about 1.9 times in Q2 2026. It refinanced debt in 2026, including issuing $500 million of 5.875% senior notes due 2034 and redeeming $400 million of 4.5% notes due 2028. The higher coupon is the price of extending maturity in a higher-rate environment.

Capex is where an ordinary free-cash-flow screen gives the wrong first impression. Total 2026 capex guidance of $920 million–$995 million is enormous relative to accounting earnings, but maintenance is only $225 million–$240 million. The remainder is primarily the choice to create additional earning assets. This does not make growth capex “free”: shareholders still fund it, and poor hospital selection would destroy value. It does mean that subtracting every dollar of development capex from earnings and calling the result sustainable owner cash systematically penalizes a company that is deliberately building hospitals with a disclosed ramp history.

The market narrative has changed alongside the business. The scandal era priced survival and credibility risk. By the post-2010 years the stock increasingly traded as a rehabilitation operator with a home-health option, and the 2018–2022 period was an “integrated post-acute” story. Since the spin, investors have gradually re-rated EHC as a pure-play IRF growth company, especially as pandemic labor pressure receded and discharges continued expanding.

Any long-term chart must be read around July 2022 with care. EHC holders received EHAB shares; the apparent ex-spin decline in EHC alone is not the shareholder’s full economic return. A 2026 comparison against pre-spin per-share data should likewise use continuing EPS rather than total historical EPS.

At $120.92, the current share price is around 19.7 times the midpoint of management’s $6.02–$6.25 2026 adjusted EPS guidance. I cannot support an exact “historical percentile” for that multiple from primary disclosures: Encompass Health does not publish a historical P/E series, and a third-party multiple-history database was not sufficiently verified for this report. The qualitative conclusion is firmer: the present valuation assumes EHC remains a growth-quality hospital operator. The equity no longer carries a turnaround multiple.

Business model, industry and horizontal analysis

Encompass Health now has one operating business. Almost all operating revenue comes from inpatient rehabilitation hospitals; “other” revenue is small. Q2 2026 inpatient revenue was $1.552 billion out of $1.597 billion total, or about 97%. That simplicity is valuable: the financial model can be reduced to patients × revenue per patient, constrained by beds and staffing.

An IRF admission usually follows an acute-care hospital stay. The patient must be medically stable enough to leave acute care but complex enough to need an intensive interdisciplinary rehabilitation program. CMS’s rules require multiple therapy disciplines, physician supervision and other hospital-level criteria; IRFs must also satisfy the 60% classification rule. The result is a meaningfully different product from skilled nursing, home health and hospice. An SNF can deliver rehabilitation, but the intensity, physician involvement and admission requirements are lower; home health moves the setting into the patient’s home; hospice treats a fundamentally different clinical objective.

Cost structure follows from that intensity. Nursing, therapists and other employees are the largest variable/semi-variable operating expense, while buildings, medical equipment, information systems and hospital administration create a meaningful fixed-cost base. Hence the importance of filling incremental beds: once a functioning hospital has its core infrastructure, additional occupied beds spread fixed overhead. At the same time, staffing cannot fall proportionally when census declines because minimum clinical coverage and hospital infrastructure remain.

Operating leverage shows up today in occupancy and labor productivity rather than an explosive margin jump. Occupancy rose materially from 72.1% in 2023 to 75.9% in 2025 while EPOB stayed around the mid-3.3 range and contract labor fell. This is healthy leverage: more patient days flowed through the network while expensive temporary staffing became less necessary.

The moat is operational and local, not conventional pricing power. Medicare decides the largest payment rate, Medicare Advantage can deny admissions, and commercial contracts are negotiated against concentrated payers. EHC’s advantage shows up instead in the ability to win referrals, recruit enough clinical staff, get hospitals built, meet IRF regulatory criteria and operate beds at high utilization.

Scale combined with referral density is the strongest moat element. With 176 hospitals across 39 states and Puerto Rico, EHC has far more IRF operating repetitions than an isolated regional facility. That generates construction expertise, clinical protocols, centralized information systems, recruiting data, payer experience and management bench depth. Scale does not eliminate local competition; healthcare remains intensely local. It lowers the cost of repeatedly solving the same problems.

Joint ventures reinforce that local network. Sixty-seven of EHC’s 176 hospitals are joint ventures, often with acute-care health systems. For the health-system partner, the model adds a specialized post-acute destination without requiring it to develop EHC’s operating capabilities from scratch. For Encompass Health, the relationship embeds the IRF inside an acute-care referral ecosystem and can reduce the risk of entering a new market cold. The price is minority economics: a successful JV grows consolidated EBITDA faster than earnings attributable to EHC shareholders.

Regulation raises another barrier. IRFs need hospital licensure, must satisfy CMS conditions, need sufficient qualified clinical staff and in many states remain subject to certificate-of-need rules or similar controls. Encompass Health’s 10-K notes that CON laws can restrict new or expanded healthcare facilities and large capital expenditures. Those barriers protect incumbent supply in some markets, and they can slow EHC itself too.

Construction knowledge is turning into part of the moat. The 2023 Investor Day showed Encompass Health standardizing hospital design and using prefabrication to shorten completion time. The same presentation projected average cost of roughly $1.2 million per bed for 2024–2025 openings and discussed a 16-month fully prefabricated development timeline versus roughly 24 months for conventional construction. What that buys is repeatability in a capital-intensive physical business, not proprietary technology in the software sense.

Technology supports the model without being the source of industry power. EHC has invested in an enterprise clinical record, referral tools, patient assessment, analytics and predictive models, including models intended to identify patients at risk of acute-care transfer. These systems can improve referral conversion and care management, but a hospital does not choose EHC because of a standalone software product. The technology is valuable because it improves a regulated clinical operation.

One thing makes the industry backdrop attractive: supply has not expanded rapidly. Encompass Health’s 2023 Investor Day, drawing on CMS and MedPAC data, put the U.S. IRF count at 1,179 in 2010 and 1,197 in 2022, only a 1.5% increase, while EHC itself had added 50 de novo hospitals over that period. The same presentation estimated an all-payer IRF market of about $14.5 billion and roughly 745,000 discharges, with a theoretical addressable market of $29 billion–$44 billion if more clinically eligible acute-care patients converted to IRF care. Those are 2023 management estimates rather than a current 2026 independent TAM, so they should be treated as directional.

Demographics help. EHC’s Investor Day cited U.S. Census projections showing the population aged 65 and older rising from about 39 million in 2010 to 55 million in 2020 and an estimated 73 million in 2030. Stroke, neurological disease, fractures and major orthopedic events are strongly age-linked, which gives rehabilitation a defensive demographic tailwind. The company is nevertheless more sensitive to policy than to GDP. What EHC runs on is a reimbursement-and-labor cycle, not a classic macroeconomic one.

Medicare policy currently gives EHC a modest nominal tailwind. The FY2026 IRF PPS update is 2.6%; FY2027 is finalized at 2.3%. Those increases are positive but not generous relative to wage and construction inflation. The business model works because volume and mix add to nominal pricing, not because Medicare alone produces high revenue growth.

MedPAC remains a structural counterweight to the idea that reimbursement will always rise comfortably. The commission reviews IRF payment adequacy annually and has historically recommended restraint or reductions when it considers sector margins excessive. Encompass Health itself has disclosed earlier MedPAC recommendations for base-rate reductions. CMS, rather than MedPAC, sets payment through rulemaking, but sustained evidence of high sector margins can eventually influence policy.

Medicare Advantage adds a second policy cycle layered on top of IRF PPS. Traditional Medicare gives EHC relatively transparent eligibility and rate rules. MA introduces payer authorization. EHC says MA generally pays less, produces lower referral conversion and frequently denies IRF admissions that management believes would qualify under traditional Medicare. That can depress both realized rate and volume. I did not find a reliable payer-specific length-of-stay disclosure; aggregate LOS was 11.9 days in Q2 2026.

The closest operating comparison is Select Medical, though it stopped being a listed comparable on June 30, 2026, when a consortium led by Robert Ortenzio, Martin Jackson and Welsh, Carson, Anderson & Stowe took it private at $16.50 per share; the NYSE filed the removal notice on July 1 and Select deregistered on July 13. Even as an operating comparison, Select is not a clean pure play. In 2025, Select Medical generated $5.453 billion of total revenue from a portfolio of critical-illness recovery hospitals, inpatient rehabilitation hospitals and outpatient rehabilitation. Its rehabilitation-hospital segment produced $278.6 million of adjusted EBITDA at a 21.6% margin. Q1 2026 rehabilitation revenue grew 14.5% to $351.9 million and segment adjusted EBITDA 15.1% to $81.1 million, a 23.0% margin. EHC’s scale in pure IRFs is vastly greater, but Select shows that roughly low-20s rehabilitation EBITDA margins are not unique to EHC.

Select Medical “became” a diversified specialty-hospital platform. The IRF operation competes directly with Encompass Health in some markets, while the critical-illness and outpatient businesses create a broader continuum. At December 2025 Select operated 38 rehabilitation hospitals, versus 176 EHC hospitals at June 2026. Its diversification creates optionality but also dilutes the purity of its IRF economics, and its critical-illness business had materially lower 2025 margins than its rehab segment. That is one reason a whole-company Select multiple cannot be transferred mechanically to EHC.

Ensign Group is more useful as a growth-quality comparison than as a clinical peer. Approximately 95.6% of Ensign’s 2025 revenue came from skilled nursing facilities. Its patients generally stay longer and receive less intensive rehabilitation than IRF patients. Ensign’s operating architecture is decentralized and acquisition-oriented, whereas EHC’s current growth is dominated by purpose-built IRF capacity. Ensign guided to $5.77 billion–$5.84 billion of 2026 revenue and $7.41–$7.61 of diluted EPS. At approximately $179.37 a share, that equates to roughly 24 times the midpoint of company guidance, above EHC’s approximately 19.7 times. A premium is defensible if investors assign Ensign greater acquisition runway and less concentration in one reimbursement system; it is not evidence that EHC itself is cheap.

Chemed sits farther away still. It owns VITAS hospice and Roto-Rooter. VITAS belongs in post-acute healthcare, but hospice economics revolve around end-of-life census, length of service and the hospice Medicare benefit. It does not compete head-on for intensive rehabilitation patients. Chemed is useful for understanding how markets value high-cash-generation, Medicare-exposed healthcare services, but its conglomerate mix makes a direct P/E comparison weak.

Enhabit was conceptually the closest “sibling” because it came from EHC, but home health/hospice sits on a lower-acuity part of the continuum and Enhabit is no longer public following its May 2026 acquisition. The transaction itself is informative: what EHC spun off became an externally acquired home-health/hospice asset, while EHC’s own valuation increasingly reflects its IRF scarcity and growth profile.

† Prices are current-market references where available; operating and earnings figures are taken from each company’s own filings or guidance. I do not publish a current Select or Chemed multiple here because the retrieved primary data do not support a clean same-date, same-definition calculation, and Select has had no market price since it was taken private on June 30, 2026. Sources: EHC filings, Select Medical filings, Ensign filings, Chemed filings.

The horizontal conclusion is stronger than a multiples table. EHC is the purest listed exposure to U.S. inpatient rehabilitation. Select proves that competitors can achieve similar hospital margins, so EHC’s moat is not monopoly pricing. Ensign proves that other post-acute models can compound at premium valuations, but its skilled-nursing economics cannot simply be imported. Chemed and the former Enhabit expose different ends of the post-acute chain. EHC’s niche is ownership and operation of the most medically intensive step between acute hospitalization and lower-acuity post-acute care.

That niche should strengthen if acute hospitals continue trying to discharge patients earlier while patients remain medically complex, provided payers permit IRF access. Its position weakens if Medicare Advantage successfully shifts clinically borderline cases to SNFs or home health. The long-term competitive battle is therefore partly between IRFs, but increasingly between sites of care.

Current fundamentals and market narrative

The latest four quarters show very little variation in the operating pattern.

Source: SEC-filed EHC earnings schedules.

Two things stand out. First, revenue did not require ever-increasing occupancy: EHC kept adding beds. Second, revenue per discharge dipped slightly sequentially from Q1 to Q2 even as year-over-year growth remained 3.9%. The current trajectory is broad rather than dependent on one unusually favorable metric.

Q2’s 5.6% discharge growth consisted of 2.8% same-store growth plus new-store contribution. The difference between total and same-store growth suggests roughly half the percentage-point increase came from facilities not yet in the comparable base. That is exactly what an investor should want to see from a construction strategy: the mature estate is still growing while recently built capacity adds incremental volume.

The occupancy question deserves more nuance than the headline. The formal Q2 occupancy increase is approximately 80 basis points year over year, not 290 basis points. At 77.4%, a naïve national view suggests 22.6% unused capacity. Operationally, much of that theoretical vacancy is unavailable to a patient in a different city. Management’s statement that around 60 hospitals exceed 90% occupancy and that expansion work now starts around 70%–75% shows why local bed availability matters more than consolidated occupancy.

This also changes the interpretation of new hospitals. EHC builds because referral markets are local, because a high-occupancy hospital cannot transport its unused demand to a low-occupancy hospital hundreds of miles away, and because a new 40–60-bed hospital can create a new referral catchment. Aggregate network fullness is not the trigger. The key execution test is whether each de novo reaches the disclosed positive-EBITDA/month-six and >70%-occupancy/month-ten pattern.

Labor gave the margin a second push in Q2. Premium labor fell to roughly $25 million, contract FTEs dropped 12.1% and EPOB improved to 3.34 from 3.39. The important forward question is whether ordinary wage inflation now absorbs the remaining agency-labor savings. Once contract usage reaches approximately 1% of staff, the easy denominator of “replace expensive agency workers with internal employees” is largely harvested.

Pricing has an unusually visible near-term bridge. The FY2027 final IRF rule’s 2.3% increase begins October 1. Medicare FFS is nearly two-thirds of EHC revenue. If volume and acuity remain stable, the final rule gives management a known positive input for Q4 2026 and the first nine months of calendar 2027. The unknowns are wage growth, case mix and MA/commercial pricing.

Medicare Advantage is currently more of a volume friction than a headline revenue-share shock. MA represented 16.2% of Q2 revenue, down from 16.9% a year earlier, while Medicare FFS rose to 65.8% from 64.5%. That mix was favorable. A sustained reversal toward MA could weaken realized price and admission conversion unless EHC’s appeal strategy or regulation changes insurer behavior.

The 89% success rate among adjudicated appeals in the admit-and-appeal pilot is potentially important because it reframes part of MA denial pressure as a process problem rather than an underlying clinical-demand problem. Scaling the pilot could add admissions, but success must be judged on more than appeal percentage. Investors need the ultimate admission conversion, cash-collection timing, administrative cost and payer response.

Management raised all three major full-year ranges after Q2. The midpoint now implies roughly $6.45 billion of revenue, $1.38 billion of adjusted EBITDA and $6.14 of adjusted EPS. Against 2025 results, those midpoints imply approximately 8.7% revenue growth, 8.8% adjusted EBITDA growth and about 10.5% adjusted EPS growth. The EPS spread reflects some combination of operating growth, below-the-line items and share repurchases.

Capital returns are now part of the narrative rather than the primary thesis. The quarterly dividend is $0.21, or $0.84 annualized, while the enlarged $1 billion repurchase authorization is material relative to a roughly $12.1 billion market capitalization. Repurchases can accelerate per-share growth if executed below intrinsic value. At a roughly 20-times current-year earnings multiple, buybacks are no longer obviously high-return simply because cash is available.

The market’s present narrative reads: “durable IRF scarcity plus construction-driven capacity compounding, with labor normalization funding part of the ramp.” It is grounded in real fundamentals: discharge growth, bed growth, falling contract labor, positive reimbursement, de novo ramps and raised guidance. The speculative layer is the multiple. Investors have started assuming those favorable variables can coexist for years.

The strongest bull evidence is that there is no single heroic assumption behind Q2. Volume rose, price/mix rose, occupied beds rose and contract labor fell. The strongest bear evidence is almost the mirror image: when every variable is favorable at once, future comparisons become harder. A 20-times earnings price needs several of those variables to remain favorable.

The central bull/bear divergence can be stated precisely. Bulls believe EHC can continue adding roughly 6–10 de novos and 80–120 beds annually, fill those beds rapidly, grow same-store discharges, maintain low-20s EBITDA economics and use MA appeals to widen the eligible-patient funnel. The company’s stated capacity-growth strategy and its historical new-hospital ramp support that case. Bears believe the apparent runway is partly pre-spent in the share price and capital budget: nearly $1 billion of annual capex, rising construction cost per bed, administratively determined Medicare rates and MA gatekeeping mean that a few points of revenue disappointment can hit both margin and the valuation multiple.

Valuation, risk, catalysts and tracking

At the August 24 close of $120.92, EHC’s market capitalization is approximately $12.1 billion. Using the midpoint of the $6.02–$6.25 adjusted EPS guidance, current-year P/E is about 19.7 times. That multiple is neither distressed nor obviously speculative. It prices EHC as a durable healthcare grower.

An EBITDA cross-check gives a similar message but requires care. The company guides to $1.365–$1.395 billion of 2026 adjusted EBITDA, and reported net leverage is approximately 1.9 times. A conventional EV/EBITDA calculation appears around the low-double-digit range, but EHC consolidates 100% of controlled JV EBITDA while common shareholders own less than 100% of those hospitals. Given $805.5 million of nonredeemable NCI and $57.9 million of redeemable NCI at June 30, a simple EV/EBITDA ratio omitting minority value understates the economic multiple. I place greater weight on attributable earnings.

Cash passthrough is high. The five-year operating-cash-flow/net-income ratio using continuing net income attributable to EHC is:

† Continuing-operations presentation across the Enhabit separation. The numerator is consolidated cash flow and therefore includes JV cash before minority-owner distributions; the ratio should not be interpreted as cash available solely to EHC common shareholders.

The maintenance/growth-capex split matters more here than at most companies. At the midpoint of 2026 guidance, total capex is $957.5 million, but only $232.5 million is maintenance. Maintenance represents about 24.3%, with roughly $725 million directed to development, capacity, technology and other non-maintenance investment.

A perfectly clean “owner earnings per share” cannot be reconstructed from public disclosure because maintenance capex is reported at the consolidated level while significant JV cash belongs economically to minority owners. Subtracting all maintenance capex from attributable earnings double-counts some JV economics; starting from consolidated OCF and failing to deduct minority cash claims creates the opposite bias. The reasonable conclusion is narrower: depreciation/noncash charges cause cash earnings to exceed accounting earnings, while the large gap between total and maintenance capex means all-in FCF materially understates the cash-generating power of the mature hospital estate.

For this reason, the primary valuation scenarios use attributable EPS and a multiple consistent with regulated hospital economics, while cash flow serves as a quality cross-check. That is more conservative than treating consolidated OCF less maintenance capex as if it all belonged to EHC shareholders.

The scenario framework assumes FY2027 earnings as the 12-month anchor and three-year EPS growth for return analysis.

† Three-year estimates assume approximately 1%, 8% and 12% EPS CAGRs respectively from the 2026 guidance midpoint, terminal P/Es of 17x, 19x and 21x, and modest cumulative dividends. These are scenario calculations, not company guidance. Source inputs are current price and EHC guidance.

This is valuation-scenario analysis within a research framework, not investment advice.

The conservative case does not require a recession. It assumes the business remains healthy but loses some of its current operating momentum: same-store discharge growth slows, new hospitals take longer to fill and reimbursement merely offsets wages. A 17.5–18 times multiple is still generous for a regulated hospital business, so $111–$118 is not a disaster valuation.

The base case assumes EHC continues to execute: low- to mid-single-digit mature-store volume growth, capacity additions that fill close to historical ramp, the finalized FY2027 reimbursement update, and no major resurgence in temporary labor. The implied $127–$138 range places current price near the lower portion of fair value rather than at a large discount.

The optimistic case requires more than an ordinary CMS update. It needs a sustained volume runway, successful expansion of MA authorization/appeal strategies, continued labor productivity and confidence that the de novo engine can reinvest several hundred million dollars annually at attractive returns. Under those conditions a low-20s earnings multiple can be defended. It cannot be defended merely because the healthcare sector is defensive.

Historical valuation offers less comfort than it would have several years ago. The present P/E is consistent with the market treating EHC as a quality grower, while the old conglomerate, scandal-recovery and post-spin-transition discounts have largely disappeared. An exact historical percentile is not reported because I could not construct a primary-source multiple history reliable enough to satisfy the report’s traceability standard.

Peer valuation offers only partial support. Ensign trades at approximately 24 times the midpoint of its 2026 EPS guidance, versus EHC at about 19.7 times. That discount is not a direct bargain signal: Ensign has different reimbursement exposure, a decentralized SNF acquisition model and a different capital-intensity profile. Select’s IRF margins validate EHC’s operating economics but Select’s diversified structure, and its June 30, 2026 take-private, rule out a clean public-market multiple comparison.

The expectation gap for the next print is concentrated in three numbers. Investors need same-store discharges to stay positive enough to prove demand is not purely construction-driven; revenue per discharge must remain consistent with the Medicare-rate and acuity bridge; and contract/premium labor must remain low enough that wage inflation does not consume the reimbursement increase. A Q3 miss in total revenue caused purely by opening timing would matter less than a same-store discharge or margin miss.

The market also needs evidence that higher capex earns returns rather than merely replaces growth that would otherwise slow. Five additional hospital openings and more than 100 existing-facility beds are scheduled for the second half of 2026. By 2027, occupancy and EBITDA ramp at those sites will become more informative than the opening count itself.

The margin-of-safety test is harsher than the fair-value exercise. Current price of $120.92 sits about 2%–9% above the conservative $111–$118 value range. Against the conservative scenario, the margin of safety is zero.

The most fragile assumption is the valuation multiple, not the near-term CMS rate. If the base 19-times multiple were cut to 70%, or roughly 13.3 times, while base earnings remained intact, the value falls from around $130 to approximately $91 a share. A good operating result cannot protect shareholders against buying too high if the market later decides a regulated hospital deserves a low-teens multiple.

A flat-earnings exercise makes the same point. If EPS remains approximately $6.14 for three years and the P/E is unchanged, the capital gain is zero and the present $0.84 annualized dividend produces only about a 0.7% yield before tax. The U.S. Treasury’s August 24, 2026 par yield curve put the 10-year yield at approximately 4.70%. Under the user’s required comparison, there is no margin of safety at this buy price.

Margin-of-safety sufficiency verdict: none.

This is close to a “good company, ordinary-to-bad entry price” case for a new investor. The distinction matters: $120.92 is not obviously excessive relative to the base operating outcome, which is why a sell case is weak. It also provides little protection against a routine execution miss.

The principal permanent-loss risks are specific.

The first is reimbursement and payer conversion. Probability is medium; impact is high. Medicare FFS is 65.8% of revenue, and MA another 16.2%. A future CMS update materially below wage inflation, combined with more MA mix, hits both revenue per discharge and referral conversion. A 100-basis-point shortfall in realized revenue growth on a roughly $6.45 billion annual revenue base is about $65 million of revenue; because fixed hospital costs do not fall proportionally, EBITDA impact would be meaningful. Observable indicators are CMS final rules, MA revenue mix, admission conversion and revenue per discharge.

The second is labor reacceleration. Probability is medium; impact is high. Contract labor is already down to 333 FTEs and premium labor to approximately $25 million in Q2, which makes another large improvement mathematically harder. If nurse and therapist shortages return, EHC could see internal wage escalation before contract FTEs visibly rise. EPOB, contract-labor percentage, premium-labor dollars and salaries/benefits as a percentage of revenue should move before the EPS damage becomes obvious.

The third is construction-return erosion. Probability is medium; impact is medium-to-high. Average de novo cost per bed had already risen from $725,000 for 2020–2021 projects to $1.2 million for the 2024–2025 cohort in the formal investor-day benchmark. With almost $1 billion of 2026 capex and 18 facilities under development, small errors in market selection can compound. The warning signal would be new hospitals taking materially longer than six months to reach positive four-wall EBITDA or ten months to pass 70% occupancy.

The fourth is minority-interest leakage. Probability is high because it is part of the model; impact is medium. Q2 noncontrolling-interest income was $53.5 million and increased with the profitability of JV hospitals. A larger JV mix can make consolidated revenue and EBITDA growth look stronger than growth in value attributable to EHC common shareholders. The relevant indicator is NCI income and cash distributions relative to consolidated EBITDA.

The fifth is valuation compression. Probability is medium; impact is high. A move from roughly 19.7 times guidance EPS to 15 times on unchanged $6.14 earnings implies a price around $92, roughly 24% below the August 24 close. A 13-times multiple implies around $80. No operational crisis is required for that outcome; slower growth plus a higher required return would suffice.

Positive catalysts over the next year are unusually tangible: the 2.3% FY2027 Medicare update begins October 1; five more hospitals and more than 100 additional beds are expected before year-end; the MA appeal pilot could be scaled; contract labor could remain below 1.2% of staffing; and the $1 billion buyback authorization gives management capacity to retire stock on weakness.

Negative catalysts are equally observable: a guidance cut, same-store discharges falling toward zero, revenue-per-discharge growth below the realized reimbursement bridge, premium labor turning upward, new hospitals missing the six-to-ten-month ramp, or a future CMS payment proposal below market-basket wage pressure.

Operating metrics come from the Q2 SEC filings; the FY2027 payment update is finalized by CMS. The October 28 Q3 report date is an external calendar estimate rather than a company-confirmed announcement as of the research cutoff, and should therefore be treated as provisional.

The first five dashboard indicators tell almost the entire operating story. Same-store discharges separate underlying referral demand from construction, while total discharges show whether new capacity is contributing. Revenue per discharge captures reimbursement and acuity, and Occupancy shows capacity pressure. Contract labor and EPOB reveal whether the margin is being purchased through expensive staffing. The rest monitor leverage, policy and payer mix.

Cross-synthesis, research conclusion, uncertainties and sources

Looking vertically, Encompass Health has proved one capability more convincingly than any other: it knows how to operate inpatient rehabilitation hospitals at national scale. The evidence sits in the post-reconstruction record, not the old HealthSouth acquisition record that the accounting scandal contaminated. EHC built a standardized IRF system, survived the pandemic labor shock, added beds while raising occupancy, separated an unrelated home-health/hospice arm, and accelerated de novo development without losing same-store volume growth.

Its past success came from several different eras and should not be blended into one heroic management narrative. The 1980s–1990s expansion benefited from real industry demand and entrepreneurial aggression, but reported financial success became unreliable because of accounting fraud. The post-2003 recovery was more clearly managerial: governance was rebuilt, noncore complexity was reduced and hospital operations regained credibility. The 2014–2022 diversification into home health was strategically coherent but eventually judged less valuable than focus. The present phase is the most analytically straightforward: EHC invests capital in new IRF capacity and attempts to fill it.

Those success factors are largely still present. Demographics continue to increase the population prone to stroke, neurological conditions and disabling orthopedic events, and IRF supply has historically grown slowly. EHC has a construction pipeline, referral relationships and a large staffing/recruiting system. CMS has finalized positive nominal reimbursement for FY2027.

What has changed is the valuation. Investors are no longer being paid for uncertainty about whether the pure-play structure works. They are being asked to pay roughly 20 times current-year earnings for a business already executing well. The valuation is rewarding both proven capability and future execution.

Horizontally, EHC’s real advantage over Select Medical is not a radically superior IRF margin; Select’s rehabilitation segment can also produce low-20s EBITDA margins. EHC’s advantage is scale and purity: more IRF markets, more construction repetitions and a management organization built almost entirely around this one care setting. Against Ensign, the advantage is clinical intensity and IRF specialization; Ensign has a more decentralized acquisition model and a different lower-acuity reimbursement system. Against home health, the advantage is that medically complex patients genuinely require a hospital-level environment. Against all of them, EHC’s weakness is the same: Medicare and insurers have more price-setting power than the provider.

The joint-venture system amplifies that advantage but complicates capital-market interpretation. A health-system JV creates a relationship with the acute hospital that produces the referrals. It may also improve local political and clinical credibility. Yet common shareholders do not own 100% of the resulting earnings. With 67 JVs and $53.5 million of Q2 earnings attributable to NCI, minority leakage is now too large to leave as a footnote. This is why attributable EPS deserves more weight than consolidated EBITDA in valuation.

The biggest thing the market may be misjudging is the shape of capacity. A 77.4% aggregate occupancy figure looks comfortable. The local evidence says many important hospitals are already constrained, with roughly 60 above 90% occupancy and management initiating expansion decisions around 70%–75%. That supports the bull case for construction. It also means future growth is increasingly capital-dependent. The same fact can be bullish operationally and bearish financially if the cost per incremental bed keeps rising.

The second potential misjudgment is Medicare Advantage. An 89% appeal win rate in the pilot makes some preauthorization denials look overly restrictive, but the sample remains limited and incomplete: only 144 of 298 cases had been adjudicated through July. Investors should not extrapolate the win rate into a full recovery of MA conversion. The more interesting evidence would be a scaled program that raises admissions without materially extending receivable days or administrative expense.

The third is labor. Pandemic normalization was an earnings catalyst that can only happen once. Contract labor has already fallen to about 1.1% of staffing. Future margin growth has to come increasingly from operational productivity, mix and occupancy rather than another dramatic agency-labor collapse. That makes ordinary wage inflation more important from here.

For the next twelve months, the decisive variables are same-store discharges, the FY2027 rate flowing through revenue per discharge, H2 hospital openings, premium labor and MA conversion. For three years, the question is whether EHC can turn approximately $700 million-plus of annual growth-oriented capital deployment into sufficiently high incremental earnings to maintain a high-single-digit or better EPS CAGR. For five years, the deepest question is policy: whether Medicare Advantage and broader post-acute payment reform continue to recognize IRFs as a distinct, medically intensive setting or increasingly push marginal cases toward cheaper alternatives.

The company becomes a materially better investment under either of two conditions. One is price: the equity falls toward the low-$90s while discharge growth, labor and reimbursement remain intact. The other is fundamental acceleration: MA conversion improves demonstrably, recent de novos hit their six-to-ten-month ramps and EHC shows that construction economics remain compelling despite higher cost per bed. The original judgment should be reconsidered negatively if same-store discharges stay below 1%, revenue per discharge falls below its reimbursement bridge, contract labor begins rebuilding or multiple new hospitals miss their disclosed ramp pattern.

Bull reasons:

• EHC has increased inpatient revenue from $3.50 billion in recast 2020 results to $5.76 billion in 2025 while adjusted EBITDA compounded faster, evidence that the post-spin IRF model can scale.
• Q2 2026 discharge growth of 5.6% included 2.8% same-store growth, so expansion is adding to rather than masking organic demand.
• Contract FTEs fell to 333 and roughly 1.1% of staffing while EPOB improved, reducing one of the largest post-pandemic margin pressures.
• New hospitals historically average positive four-wall EBITDA by month six and more than 70% occupancy by month ten, giving the large construction pipeline a documented operating-ramp precedent.
• The FY2027 IRF PPS update is already finalized at +2.3%, providing a known reimbursement tailwind from October 1, 2026 rather than a merely proposed one.

Bear reasons:

• Current valuation of roughly 19.7 times 2026 guidance leaves no discount to the conservative $111–$118 scenario and relies on continued growth execution.
• Medicare and Medicare Advantage supply approximately 82% of revenue, leaving the company structurally exposed to administratively set prices and authorization behavior it does not control.
• Total 2026 capex is expected to reach $920 million–$995 million, and the latest formal de novo benchmark showed construction cost at about $1.2 million per bed, making future growth materially capital-intensive.
• Labor normalization is approaching diminishing returns because contract employees are already only about 1.1% of total FTEs; ordinary wage inflation can increasingly offset remaining premium-labor savings.
• Consolidated growth increasingly includes minority-owned JV economics: Q2 NCI absorbed $53.5 million of income, so headline EBITDA growth can exceed common-shareholder earnings growth.

Pre-mortem script one: during 2027–2028, Medicare Advantage penetration continues rising and large plans tighten IRF authorization while traditional Medicare rate updates settle around 1%–2%. EHC’s MA appeal process proves administratively costly and does not restore enough referral conversion. Same-store discharge growth falls below 1%, revenue per discharge grows only 1.5% while wages rise 3.5%, and adjusted EBITDA margin compresses by roughly 150–200 basis points. The market cuts EHC from about 20 times earnings to 14–15 times. With EPS slipping toward $5.5–$6.0 rather than advancing toward $7+, the share price could land in roughly the $80–$90 range, a decline of around 30%. The transmission path is payer restriction → lower admissions/rate → fixed-cost deleverage → EPS miss → multiple compression. The payer and pricing exposures are already visible in current disclosures.

Pre-mortem script two: EHC keeps building aggressively into 2027–2029 after construction costs remain above $1 million per bed. Several large new hospitals take 18–24 months rather than roughly ten months to reach 70% occupancy because local staffing and referral assumptions prove too optimistic. Growth capex stays around $700 million-plus annually, net leverage rises above 2.5 times, buybacks slow, and earnings grow only 2%–3%. A 13–15-times mature-hospital multiple applied to roughly $6.5 of earnings creates an $85–$98 equity value. The company remains solvent and clinically relevant; shareholders still suffer because capital was deployed below the return embedded in the original share price.

The final judgment separates company quality from security price. Encompass Health is one of the clearer healthcare compounders available in the public market because its growth mechanism can be observed: build or expand beds, recruit the staff, win the referral, fill the bed and receive a largely regulated payment. The company has executed that process well. Q2 2026 provides strong evidence: discharges +5.6%, revenue per discharge +3.9%, inpatient revenue +9.8%, lower contract labor and higher full-year guidance.

The present price asks an investor to believe much of that can continue. At $120.92, EHC is inside the base-case hold zone but above conservative value. Imminent financial distress is not the risk. The risk is the combination of regulated pricing, MA utilization management, rising development cost and a valuation multiple that can fall sharply if growth normalizes.

For an existing long-term holder, the balance of evidence supports continuing to own rather than exiting a high-quality operation solely because it is no longer cheap. For a new investor, patience has more value. A price around $89–$94 would place the shares at least 20% below the conservative valuation framework while still allowing the investor to benefit from the same construction, demographic and labor-normalization thesis.

【Company-profile scores】

• Fundamental quality: high
• Growth: high
• Moat: medium
• Financial soundness: strong
• Management credibility: high
• Valuation attractiveness: medium
• Risk level: medium
• Suitable investor type: long-term growth

【Investment rating】

Rating: Hold

• One-line thesis: Strong discharge growth and proven de novo execution support compounding, but roughly 20x current-year earnings leaves no conservative margin of safety.
• Current-price classification: acceptable hold.
• Whether to wait for a better price: yes. For new capital, the preferred trigger is $89–$94 with no material deterioration in same-store discharges, labor or CMS reimbursement. The opportunity cost is missing continued EPS compounding while cash/Treasuries currently offer a roughly 4.7% 10-year yield.
• Target holding horizon: 3–5 years.
• Expected annualized return: approximately -3% conservative, 7%–8% base and 15% optimistic over a three-year scenario horizon.
• Max-loss risk: roughly 30%–40% in a combined reimbursement/capacity/multiple failure; a 13-times multiple on $5.5–$6.5 of earnings produces roughly $72–$85 at the harsher end.
• Reassessment triggers: same-store discharge growth below 1% for two consecutive quarters; revenue-per-discharge growth below 2% after the FY2027 rate becomes effective; contract labor exceeding 1.5% of FTEs; net leverage above 2.5 times; or multiple de novos requiring materially more than ten months to exceed roughly 70% occupancy.

【Ideal Buy Price】89–94 USD

Basis: at least a 20% discount to the $111–$118 conservative 12-month value range, while assuming the operating thesis remains intact.

【Valuation Range】

• current: 120.92 (close as of 2026-08-24)
• bear (conservative · ideal buy zone): [89, 94]
• base (fair · acceptable hold zone): [115, 145]
• bull (optimistic · above the clearly-overvalued line): [170, 185]

The range is intentionally discontinuous. $95–$114 is attractive relative to current price but does not meet the report’s required 20%-below-conservative standard for an “ideal” entry. $146–$169 is richer than the chosen hold zone but has not crossed the threshold of approximately 10% above the optimistic valuation. The gaps prevent the labels from claiming more precision than the underlying assumptions provide.

Research uncertainties are concentrated in five places. First, Encompass Health does not disclose a quantitative split of revenue-per-discharge growth between pure reimbursement, acuity and other mix; the estimated 2.2–2.8 point rate contribution is an inference from payer mix and known rate updates. Second, payer-specific length of stay, particularly Medicare Advantage versus traditional Medicare, is not disclosed in a form that supports the requested comparison. Third, recent individual de novo project ROIC is not disclosed, so occupancy and EBITDA ramp are used instead of fabricated returns. Fourth, the exact 1986 IPO offer price and gross proceeds could not be independently verified from a suitable primary electronic document. Fifth, an exact current historical P/E percentile was not produced because a fully traceable primary-source valuation time series is unavailable.

Source hierarchy for the report was Encompass Health’s 2025 Form 10-K, Q1/Q2 2026 Forms 10-Q and SEC-filed earnings materials; CMS FY2026 and FY2027 IRF PPS rulemaking; CMS IRF classification guidance; MedPAC; SEC filings from Select Medical, Ensign, Chemed and Enhabit; U.S. Treasury yield data; and SEC/DOJ records for the HealthSouth history. Secondary sources were used only where the requested fact is intrinsically market-data based or primary records were unavailable, chiefly the August 6 share-price reaction and the estimated next earnings date.

Other tickers mentioned

• SEM.US: Select Medical is the closest operating IRF competitor, although it was taken private on June 30, 2026 and its critical-illness and outpatient businesses make whole-company valuation imperfect.
• ENSG.US: Ensign Group provides a high-growth skilled-nursing benchmark and trades on a different post-acute reimbursement model.
• CHE.US: Chemed’s VITAS hospice operation provides a Medicare-exposed post-acute cash-flow comparison but serves a fundamentally different clinical need.
• EHAB.US: historical ticker of the home-health and hospice business spun out of EHC in 2022 and taken private in May 2026.
• HCA.US: acute-care hospitals are major upstream referral sources for rehabilitation and useful context for hospital labor and reimbursement, but not direct valuation peers.
• UHS.US: another acute-care hospital reference point whose reimbursement and labor economics overlap with EHC but whose clinical setting differs materially.

This report is based on public information and does not constitute investment advice. Markets carry risk; invest with caution.